GB2463530A - The extraction of pharmacological agents from medicinal herbs using subcritical water - Google Patents

The extraction of pharmacological agents from medicinal herbs using subcritical water Download PDF

Info

Publication number
GB2463530A
GB2463530A GB0817353A GB0817353A GB2463530A GB 2463530 A GB2463530 A GB 2463530A GB 0817353 A GB0817353 A GB 0817353A GB 0817353 A GB0817353 A GB 0817353A GB 2463530 A GB2463530 A GB 2463530A
Authority
GB
United Kingdom
Prior art keywords
extract
extraction
botanical
water
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB0817353A
Other versions
GB0817353D0 (en
GB2463530A9 (en
GB2463530B (en
Inventor
Gary William Wheatley
Kenneth Davison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0817353.6A priority Critical patent/GB2463530B/en
Publication of GB0817353D0 publication Critical patent/GB0817353D0/en
Priority to PCT/GB2009/002229 priority patent/WO2010034971A2/en
Publication of GB2463530A publication Critical patent/GB2463530A/en
Publication of GB2463530A9 publication Critical patent/GB2463530A9/en
Application granted granted Critical
Publication of GB2463530B publication Critical patent/GB2463530B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for preparing an extract containing pharmacologically active constituents from certain traditionally used medicinal herbs comprises extracting the botanical raw material with subcritical water and then removing the water to give a pharmaceutically acceptable extract. The extraction may be conducted at 200-230°C and/or 70-85 bar. The medicinal herb may be Valerian officinalis, rosmarinus officinalis (rosemary), matricaria recuitita (german chamomile), zingiber officinale (ginger) or cassia angustifolia (senna). These sub-critical water extracts may be similar in composition to those extracts obtained by means of methanolic extraction. The extract may be formulated as a self emulsifying drug delivery system in order to improve the bioavailability of the active constituents: a formulation may comprise the extract, lauroyl macrogolglyceride and surfactant.

Description

I
A Method of Preparing Pharmacologically Active Extracts from Certain Medicinal Herbs in Traditional use in Europe Without the Use of an Organic Solvent.
FIELD OF THE iNVENTION.
This invention relates to a method of producing an extract from certain herbs, used traditionally in Europe for their medicinal value, without the use of an organic solvent.
BACKGROUND TO THE INVENTION.
Higher plants are unsurpassed in their ability to produce biologically active molecules often of great complexity. These plant "secondary metabolites" have proven a fruitful source of new pharmaceuticals. Often the first use of these compounds as been in the form of traditional herbal medicines. However the structure of the active compounds is frequently so complex that synthetic chemistry can provide no economically viable route to the molecule and this has to be isolated from the plant material.
Simple aqueous extraction of the biomass almost invariably results in a complex extract in which the target compound is diluted by a range of other unwanted phytochemicals derived from the plant, including proteins, sugars and other carbohydrates.
Extraction with a lower alcohol, typically ethanol or methanol, is traditionally a very popular means of obtaining a pharmacologically active preparation from a medicinal herb. The use of an alcohol has the advantage over an aqueous extraction that the highly polar compounds such as carbohydrates, sugars and proteins (which generally are inactive and serve only to add bulk and dilute the concentration of the active compounds) are not extracted.
However the obvious disadvantages of the use of an alcohol in extraction is that it is flammable, necessitating expensive precautions during processing, and also the recovery of the organic solvent for disposal or for further purification and re-use is required. Methanol in addition is highly toxic, and residual levels must be rigorously limited in a pharmaceutical preparation. Indeed due to this high toxicity of methanol, it is frequently substituted by a mixture of the more polar water and the less polar ethanol to produce an extraction solvent of comparable polarity.
A more recent approach that has also successfully applied is the production of a high potency extract, standardised on the content of the active substance, using extraction with a subcritical fluid or liquefied gas, most commonly carbon dioxide. One drawback of LCO2 extraction is that the technique is limited to less polar compounds.
It will not extract the compounds most readily soluble in methanol or aqueous alcohol mixtures, including the important class of flavonoids and other polyphenolic compounds such as lignans. The importance of polyphenolic compounds as potential new drugs is increasingly being recognised; with anti-inflammatoiy activity, anti-bacterial activity and a wide range of activities related to suppression of tumour growth (including inhibition of angiogenesis and reversal of multidrug resistance) being well established.
A more recent example of a high pressure liquefied gas which is being evaluated as an extraction agent and which promises capabilities not exhibited by LCO2 is high pressure superheated water at >150°C. Importantly, it is capable of solubilising more polar compounds than LCO2 extraction. Subcritical water has the unique property that the polarity changes in a well established and predictable manner as temperature is increased; thus at 150°C subcritical water has a polarity equivalent to a 50:50 mixture of water and alcohol under normal conditions, and the polarity further decreases to a value equivalent to methanol alone at 230°C. It is this property that is the basis of this invention: by employing subcritical water it is found that extracts equivalent in composition to those produced by methanol can be obtained without the disadvantages resulting from the use of a toxic and flammable solvent.
The traditionally used medicinal herbs for which extraction with subcritical water is described in this invention all produce an extract with methanol that has been widely reported in the literature to contain flavonoid or other phenolic compounds which produce important pharmacological effects as follows: The methanolic extract of Valerian officinalis root contains valerenic acid that is now established as the principal active substance responsible for the sedative and anxiolytic action of the traditionally used extracts.
The methanolic extract of Rosmarinus officinalis (rosemaiy) leaves contains high levels of rosmarinic acid and related compounds which are known to be largely responsible for the strong anti-inflammatory and anti-bacterial activity of the herb.
The methanolic extract of Matricaria recutita (German chamomile) flowers contains significant levels of apigenin and related flavonoids that are known to exhibit a range of anti-inflammatory actions.
The methanolic extract of Zingiber officinale (ginger) root contains significant levels of the gingerol and shogaol components known to be responsible for the anti-emetic and anti-inflammatory actions.
The methanolic extract of Cassia angutfolia (senna) leaves contains the anthraquinone glycosides sennosides A-D that are known to be responsible for the laxative action of the herb.
Thus as the subcritical water extract of the herbs as described in this invention are demonstrated to exhibit a composition essentially similar to that of the corresponding methanolic extract then it can be expected that these extracts will exhibit comparable pharmacological properties to these and to the compound contained therein.
A problem limiting the use of flavonoids and related polyphenolic compounds in therapeutic situations in which systemic treatment rather than local application is required is poor water solubility. This is largely responsible for the low circulating plasma levels after a single oral dose and results in the majority of the dose being excreted without absorption.
Hence this invention also describes self emulsifying formulations which increase the water solubility of these compounds, thus increasing their oral bioavailability and therapeutic efficacy.
SUMMARY OF THE INVENTION.
Example 1.
The extraction apparatus consists of: * Two suitable stainless steel vessels capable of resisting high temperature and pressure connected by stainless steel tubing, the first to act as a reservoir in which subcritical water is produced prior to introduction to the second extraction vessel. These are contained in a thermostatted oven.
* The first reservoir is connected via an inlet valve to a high pressure pump outside the thermostatted oven.
* The extraction vessel is also connected via an outlet valve to a stainless steel receiver vessel outside the thermostatted oven but maintained at approximately 90°C.
* A valve from the receiver vessel allows the solution that accumulates to be transferred to a suitable storage vessel.
A schematic representation of a suitable arrangement of the extraction apparatus is provided as Figure 1.
Coarsely ground valerian root botanical raw material is packed into the stainless steel extraction vessel. The extraction vessel is then filled with deionised water (equivalent to approximately four times the mass of botanical raw material employed) and the temperature and pressure of the extraction vessel gradually raised to respectively 230°C and 85 bar. The extraction vessel is then held at these conditions for up to 15 minutes before the resulting solution is forced from the vessel by passing a second quantity of subcritical water into the system to continue the extraction. In all four portions of subcritical water are used to extract the botanical raw material in the manner described above.
Alternatively the same extraction may be achieved in a dynamic mode by passing the same quantity of subcritical water maintained at 230°C and 85 bar through the botanical raw material packed in the extraction vessel over the course of approximately 1 hour.
The extract is isolated from the solution resulting from the extraction by removing the water by evaporation, the final stages of which are preferably carried out under reduced pressure.
Alternatively the extract may be isolated from the solution resulting from the extraction by removing the water by the process of either freeze drying or spray drying.
A TLC fingerprint representative of the extract (also termed a botanical drug substance) produced in this example is given in Figure 2.
Example 2.
A method as described in example I wherein the botanical raw material is ground rosemary leaves.
A TLC fingerprint representative of the extract produced in this example is given in Figure 3.
Example 3.
A method as described in example 1 wherein the botanical raw material is ground flowers of German chamomile.
A TLC fingerprint representative of the extract produced in this example is given in Figure 4.
Example 4.
A method as described in example 1 wherein the botanical raw material is ground ginger root.
A TLC fingerprint representative of the extract produced in this example is given in Figure 5,
Example 5.
A method as described in example I wherein the botanical raw material is ground senna leaves.
A TLC fingerprint representative of the extract produced in this example is given in Figure 6.
While the preferred embodiments of the invention have been described above, it will be recognised and understood that various modifications may be made therein, and the appended claims are intended to cover all such modifications which may fall within the spirit and scope of the invention.
Example 6.
A Self Emusifying Drug Delivery System (SEDDS) formulation for oral administration of the extracts containing the poorly water soluble polyphenols can be prepared as follows: Extract (selected from the extracts produced in Examples 1-5) 15% w/w Lauroyl macrogoiglycerides EP (e.g Gelucire 44/14) 65-85% w/w Surfacant (e.g Cremophor RH4O or Labrafac) 0-20% w/w The extract is dispersed with stirring in the molten lauroyl macrogolglycerides at 70- 80°C. The surfactant is then added and stirring continued for a further 5 minutes.
Using suitable automatic or manual equipment the molten mixture is then dispensed into two piece hard shell gel capsules that are then sealed.
Example 7a
A cream formulation for topical application of the extracts can be prepared as follows: Extract (selected from the extracts produced in Examples 2-3) 2% w/w Cetostearyl alcohol EP 7% w/w Macrogol cetostearyl ether (e.g Cremophor A61A25) 3% w/w Liquid paraffin EP 12% w/w Parabens (e.g. Nipastat) 0.2% w/w Deionised water 67.8% w/w Propylene Glycol EP 8% wlw The extract is dispersed in the propylene glycol at 70-80°C with stirring. All other ingredients except the water are mixed at 80°C and then added with stirring to the water that was heated separately to 80°C. The dispersion of extract in propylene glycol is then added to this mixture maintained at 70-80°C with stirring. The formulation is then filled into tubes.
Example 7b
A hydroalcoholic gel formulation for topical application of the extracts can be prepared as follows: Extract (selected from the extracts produced in Examples 2-3) 2% w/w Ethanol EP 44% w/w Carbomer (e.g. carbopol 980 NF) 3% w/w Deiomsed water 51% wlw Sodium hydroxide (aq) qs to neutralise The extract is dissolved in the ethanol at 50-60°C with stirring. The carbomer is then added slowly to the water with rapid stirring. The extract solution is then added to the aqueous carbomer whilst stirring. The resulting mixture is then neutralised by slowly adding aqueous sodium hydroxide to produce a smooth semi-solid.
The formulation is then filled into tubes.

Claims (9)

  1. CLAIMS1. A method of preparing an extract containing pharmacologically active constituents from certain traditionally used medicinal herbs comprising reduction of the particle size of the botanical raw material as appropriate, extracting the botanical raw material with subcritical water, and then removing the water from the resulting solution to produce a pharmaceutically acceptable extract.
  2. 2. The method according to claim 1-6 wherein the extraction is carried out at a temperature in the range 150-260°C, and most preferably in the range 200-230°C.
  3. 3. The method according to claim 1-6 wherein the extraction is carried out at a pressure in the range 15-100 bar sufficient to maintain the water in the liquid phase, and most preferably at 70-85 bar 4. The method according to claims 1-6 wherein the medicinal herb is selected from the group consisting of the traditionally used parts of Valerian officinalis, Rosmarinus officinalis (rosemary), Matricaria recuitita (german chamomile), Zingiber officinale and Cassia angustfolia (senna).5. The method according to claim 1-6 wherein the water is removed to yield the extract by evaporation.6. The method according to claim 1-6 wherein the water is removed to yield the extract by freeze drying or spray drying.7. The method according to any preceding claim wherein the extraction of valerian root, produces an extract with a TLC fingerprint substantially as illustrated in Figure 2, which is essentially similar to the corresponding methanolic extract and exhibiting a significant spot attributable to valerenic acid.8. The method according to any preceding claim wherein the extraction of rosemary leaves produces an extract with a TLC fingerprint substantially as illustrated in Figure 3, which is essentially similar to the corresponding methanolic extract and exhibiting a significant spot attributable to rosmarinic acid.9. The method according to any preceding claim wherein the extraction of German chamomile flowers produces an extract with a TLC fingerprint substantially as illustrated in Figure 4, which is essentially similar to the corresponding methanolic extract.10. The method according to any preceding claim wherein the extraction of ginger root produces an extract with a TLC fingerprint substantially as illustrated in Figure 5, which is essentially similar to the corresponding methanolic extract and exhibiting a significant spot attributable to 6-shogaol and to 6-gingerol.11. The method according to any preceding claim wherein the extraction of senna leaves produces an extract with a TLC fingerprint substantially as illustrated in Figure 6, which is essentially similar to the corresponding methanolic extract and exhibiting a significant spots attributable to respectively sennosides A,B,C, and D. * 7 12. The use of a botanical drug as claimed in any of the preceding claims that consist essentially of botanical drug substances.13. The use of a botanical drug as claimed in claim 12 further comprising excipients.14. The use of a botanical drug as claimed in claim 12 wherein the botanical drugs substances comprise total extracts derived from the botanical raw materials.15. The use of a botanical drug as claimed in claim 12 wherein the botanical drugs substances comprise more refined fractions derived from the total extracts of the botanical raw materials.16. The use of a botanical drug as claimed in claim 12 wherein the botanical drugs substances are standardised extracts..17. The method according to any preceding claim wherein the pharmacologically active extract is formulated in a self emulsifying drug delivery system to improve the oral bioavailability of the active constituents.18. The method according to claim 17 wherein the self emulsifying drug delivery system is based on the formulation described in Example 6.19. The method according to claims 17-18 wherein the pharmacologically active extract is selected from the list of the subcritical water extracts of valerian root, rosemary leaves, German chamomile flowers and ginger root.20. The method according to any preceding claim wherein the pharmacologically active extract is formulated in a topical vehicle formulated to increase bioavailability of the active constituents.21. The method according to claim 20 wherein the topical vehicle is based on the formulation described in Example 7.22. The method according to claim 20-21 wherein the pharmacologically active extract is the subcritical water extract of rosemary leaves or German chamomile flowers, either alone or in combination.* amended claims have been filed as follows:CLAIMS1. A method of preparing an extract containing pharmacologically active constituents from certain traditionally used medicinal plants, comprising reduction of the particle size of the raw material as appropriate, extracting the botanical raw material with sub-critical water, and then removing the water from the resulting solution to produce a pharmaceuticallyacceptable extract.2. The method according to claims 1-6 wherein the extraction is carried out at a temperature in the range 150-230°C, and most preferably in the range 200-230°C.3. The method according to claim 1-6 wherein the extraction is carried out at a pressure in the range 15-100 bar sufficient to maintain the water in the liquid phase, and most preferably at 70-8 5 bar.
  4. 4. The method according to claims 1-6 wherein the medicinal plant is selected from the group consisting of the traditionally used parts of Valeriana officinalis (valerian) Malricaria recutila (German chamomile), Zingi her officinale (ginger) and Cassia angustfo1ia (senna), and also including species closely related to any of the foregoing.
  5. 5. The method according to claims 1-6 wherein the water is removed to yield the extract by evaporation.
  6. 6. The method according to claims 1-6 wherein the water is removed to yield the extract by freeze diying or spray drying,
  7. 7. The method according to any preceding claim wherein the sub-critical water extraction of Valeriana officinalis (valerian) or a closely related species produces an extract with a mc fingerprint substantially as illustrated in Figure 2, which is essentially similar to the corresponding methanol extract and exhibits a significant spot due to valerenic acid.
  8. 8. The method according to any preceding claim wherein the sub-critical water extraction of Matricaria recutita (German chamomile) or a closely related species produces an extract with a TLC fmgerprint substantially as illustrated in Figure 3, which is essentially similar to the corresponding methanol extract.
  9. 9. The method according to any preceding claim wherein the sub-critical water ***. extraction of Zingi her officinale (ginger) or a closely related species produces an extract with * a TLC fingerprint substantially as illustrated in Figure 4, which is essentially similar to the * corresponding methanol extract and exhibiting significant spots due to 6-gingerol & 6-shoagaol.****.. * *10. The method according to any preceding claim wherein the sub-critical water * extraction of Cassia angustfo1ia (senna) or a closely related species produces an extract with a TLC fingerprint substantially as illustrated in Figure 5, which is essentially similar to the :. corresponding methanol extract and exhibiting significant spots attributable to respectively * setmosides A-D. ***S11. The use of a botanical drug substance as claimed in any of the preceding claims that consist essentially of botanical drug substances.12. The use of a botanical drug as claimed in claim 11 further comprising excipients.13. The use of a botanical drug as claimed in claim 11 wherein the botanical drug substances comprise total extracts derived from the botanical raw materials.14. The use of a botanical drug as claimed in claim 11 wherein the botanical drug substances compnse more refined fractions derived from the total extracts of the botanical raw materials.15. The use of a botanical drug as claimed in claim 11 wherein the botanical drug substances are standardised extracts.16. The method according to any preceding claim wherein the pharmacologically active extract is formulated in a self emulsif,'mg drug delivery system to improve the oral bioavailability of the active constituents.17. The method according to claim 16 wherein the self emulsif'ing drug delivery system is based on the formulation described in Example 5.18. The method according to claims 16-17 wherein the pharmacologically active extract as described in any preceding claim is selected from the list of subcritical water extracts of Valeriana officinalis (valerian) Matricaria recutita (German chamomile), Zingiber officinale (ginger) and Cassia angustfolia (senna), and also including species closely related to any of the foregoing.19. The method according to any preceding claim wherein the pharmacologically active extract is formulated in a topical vehicle formulated to increase efllcacy of the active constituents.20. The method according to claim 19 wherein the topical vehicle is based on the formulations described in Examples 6 & 7 21. The method according to claim 19-20 wherein the pharmacologically active extract as described in any preceding claim is selected from the list of subcritical water extracts of * Valeriana officinalis (valerian) Malricaria recutita (German chamomile), Zingiber officinale * (ginger) and Cassia angusqfolia (senna), and also including species closely related to any of *:: the foregoing.SSS* .5 * .S S..S S. * * * **. 5.S
GB0817353.6A 2008-09-23 2008-09-23 The sub-critical water extraction of German Chamomile flowers Expired - Fee Related GB2463530B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0817353.6A GB2463530B (en) 2008-09-23 2008-09-23 The sub-critical water extraction of German Chamomile flowers
PCT/GB2009/002229 WO2010034971A2 (en) 2008-09-23 2009-09-17 Sub-critical water extraction of medicinal plants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0817353.6A GB2463530B (en) 2008-09-23 2008-09-23 The sub-critical water extraction of German Chamomile flowers

Publications (4)

Publication Number Publication Date
GB0817353D0 GB0817353D0 (en) 2008-10-29
GB2463530A true GB2463530A (en) 2010-03-24
GB2463530A9 GB2463530A9 (en) 2010-04-21
GB2463530B GB2463530B (en) 2012-08-08

Family

ID=39952010

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0817353.6A Expired - Fee Related GB2463530B (en) 2008-09-23 2008-09-23 The sub-critical water extraction of German Chamomile flowers

Country Status (1)

Country Link
GB (1) GB2463530B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2476070A (en) * 2009-12-10 2011-06-15 Kenneth Davison Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica
CN103163260A (en) * 2011-12-16 2013-06-19 成都康弘制药有限公司 Fingerprints of drugs and determination method thereof
CN105866319A (en) * 2016-04-20 2016-08-17 广西壮族自治区梧州食品药品检验所 Method for qualitatively identifying baicalin in Qinghouliyan granules by thin-layer chromatography

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
CN1692924A (en) * 2005-02-25 2005-11-09 广州中医药大学 Ginger extractive, prepn. method and use thereof
JP2006160825A (en) * 2004-12-03 2006-06-22 Tsuno Rice Fine Chemicals Co Ltd Antioxidant composition
CN1820771A (en) * 2005-12-14 2006-08-23 浙江大学 Method for extracting fat soluble component in Chinese medicine red sage root by subcritical water

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
JP2006160825A (en) * 2004-12-03 2006-06-22 Tsuno Rice Fine Chemicals Co Ltd Antioxidant composition
CN1692924A (en) * 2005-02-25 2005-11-09 广州中医药大学 Ginger extractive, prepn. method and use thereof
CN1820771A (en) * 2005-12-14 2006-08-23 浙江大学 Method for extracting fat soluble component in Chinese medicine red sage root by subcritical water

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Eur. Food Res. Technol (2002), 215, 158-163, Ollanketo et al. *
Food Chemistry 98 (2006) 136-148 Herrero et al. *
J. Agric. Food Chem. 1998, 46, 5205-5209, Basile et al. *
J. Agric. Food Chem. 2003, 51, 375-382, Ibanez et al. *
Talanta, 51, 2000, 1179-1195, Gamiz-Gracia et al. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2476070A (en) * 2009-12-10 2011-06-15 Kenneth Davison Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica
CN103163260A (en) * 2011-12-16 2013-06-19 成都康弘制药有限公司 Fingerprints of drugs and determination method thereof
CN103163260B (en) * 2011-12-16 2014-12-24 成都康弘制药有限公司 Determination method of fingerprints of drugs
CN105866319A (en) * 2016-04-20 2016-08-17 广西壮族自治区梧州食品药品检验所 Method for qualitatively identifying baicalin in Qinghouliyan granules by thin-layer chromatography

Also Published As

Publication number Publication date
GB0817353D0 (en) 2008-10-29
GB2463530A9 (en) 2010-04-21
GB2463530B (en) 2012-08-08

Similar Documents

Publication Publication Date Title
GB2463531A (en) The extraction of pharmacological agents from medicinal herbs using subcritical water
WO2010034971A2 (en) Sub-critical water extraction of medicinal plants
JP6381755B2 (en) Pharmaceutical composition containing herbal medicine (see)
CN103096907B (en) Can be used for reducing inflammation the preparation containing Echinacea angustifolia and the extract of Rhizoma Zingiberis Recens with peripheral pain
US10967030B2 (en) Traditional Chinese medicine composition for treating psoriasis and method for preparing the same
AU2008286868B2 (en) Xanthohumol-enriched hop extract
CN100544744C (en) Method, its application in antiinflammatory and analgesic of extraction and purification active component from stem of Caulis Lonicerae
JP2005511641A (en) Ginger extract formulation
GB2476070A (en) Subcritical water extraction of Hawthorn Crategus monogyna, Pueraria lobata and Centella asiatica
US20210283208A1 (en) Process for preparing an herbal extract and compositions thereof
GB2480459A (en) Subcritical water extraction methods and apparatus
GB2463530A (en) The extraction of pharmacological agents from medicinal herbs using subcritical water
Jenny et al. Antibacterial activity of aerial part of extract of Elephantopus scaber Linn
JP4117029B2 (en) Harpagophytum Procumbens and / or extract extracted from Harpagophytum hei heridens, process for producing the same and use thereof
GB2471293A (en) The extraction of pharmacological agents from medicinal herbs using subcritical water
WO2009100587A1 (en) A drug composition for treatment and prevention of ischemic stroke and its preparation methods
US20230355695A1 (en) Chebulinic acid and its enriched fraction from the fruits of terminalia chebula for treatment of benign prostatic hyperplasia (bph) and its preparation thereof
GB2490265A (en) The Sub-critical water extraction of Senna leaves
Alanazi et al. Protective role of Dodonaea viscosa extract against streptozotocin-induced hepatotoxicity and nephrotoxicity in rats
CN117255627A (en) Extraction and application of bioactive compounds in silybum marianum plant material
Muhammad et al. Nephroprotective Effects of Morus Alba Linn against Isoniazid-Induced Toxicity in Albino Rabbits.
CN100363018C (en) Honeysuckle flower soft capsule and preparation method thereof
US20230001326A1 (en) Process for extracting bioactive compounds from plant materials
Khaksarian et al. Antinociceptive Effects and Acute Toxicity of Nectaroscordum koelzi ex-tract‎ in Mice
CN105106317A (en) Preparation method and application of Southeast Asia herbal medicine combination extract

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20140923